Lengyel Gabriella, Fehér János
Semmelweis Egyetem, Altalános Orvostudományi Kar, II. Belgyógyászati Klinika, Budapest Szentkirályi u. 46., 1088.
Orv Hetil. 2010 Jul 18;151(29):1177-81. doi: 10.1556/OH.2010.28925.
Hepatocellular carcinoma (HCC) is the sixth most common cause of cancer-related death worldwide. Primary hepatocellular carcinoma can be found most frequently (80-90%) in patients with liver cirrhosis. The most frequent causes of liver cirrhosis are chronic hepatitis B and C virus infections and chronic alcohol consumption. The treatment and elimination of the etiological factors decreases the risk of HCC. The authors summarize the literary data, where effect of modern antiviral treatment has been examined according to the occurrence of HCC. It can be stated, that the antiviral therapy (interferon and nucleoside analogues) is able to decrease the risk of HCC or the recurrence of the tumor after curative treatment of HCC, in case of non responder state, as well. Drugs used for the insurance of equilibrium in redox state can also help in the decrease of HCC risk.
肝细胞癌(HCC)是全球第六大常见的癌症相关死亡原因。原发性肝细胞癌最常见于肝硬化患者(80-90%)。肝硬化最常见的病因是慢性乙型和丙型肝炎病毒感染以及长期饮酒。病因因素的治疗和消除可降低HCC风险。作者总结了文献数据,其中根据HCC的发生情况研究了现代抗病毒治疗的效果。可以说,抗病毒治疗(干扰素和核苷类似物)能够降低HCC风险或HCC根治性治疗后肿瘤复发的风险,在无应答状态下也是如此。用于维持氧化还原状态平衡的药物也有助于降低HCC风险。